世界の心的外傷後ストレス障害 (PTSD) 市場 – 2030 年までの業界動向と予測

心的外傷後ストレス障害（PTSD）市場分析と規模

世界の PTSD 市場は着実に成長しており、今後も拡大が見込まれています。PTSD の罹患率の増加、認知度および診断率の上昇が市場の成長を牽引しています。トラウマとなる出来事の増加、軍事展開、自然災害、テロ攻撃などの要因が、PTSD 治療の需要に寄与しています。

データブリッジ市場調査は、2022年に7億5,030万米ドルであった世界の心的外傷後ストレス障害（PTSD）市場は、2030年までに10億3,795万米ドルに急増し、予測期間中に4.1％のCAGRを達成すると予測しています。ヘルスケアへの投資の増加により、「抗うつ薬」が世界の（PTSD）市場の製品セグメントを支配しています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、データブリッジ市場調査がまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みが含まれています。

心的外傷後ストレス障害（PTSD）市場の範囲とセグメンテーション

Market Definition

The global PTSD market includes pharmaceuticals, psychotherapeutic interventions, digital health solutions, diagnostic tools, and other supportive services that contribute to the prevention, diagnosis, and treatment of PTSD. The market encompasses various stakeholders such as pharmaceutical companies, mental health service providers, research organizations, government bodies, and advocacy groups working together to address the impact of PTSD and improve the lives of individuals affected by the disorder.

Global Post-Traumatic Stress Disorder (PTSD) Market Dynamics

Drivers

• Rising awareness of PTSD symptoms

There is a growing awareness of mental health issues, including PTSD, among the general public, healthcare professionals, and policymakers. Increased awareness leads to early detection and intervention, creating a higher demand for effective treatments and interventions. Public campaigns, educational initiatives, and media attention help reduce stigma and encourage individuals to seek help for their PTSD symptoms.

• Government Initiatives

Governments and public health organizations worldwide have recognized the significant impact of PTSD on individuals and society. They have implemented initiatives, policies, and funding support to improve PTSD care, promote research, and enhance mental health services. Government initiatives drive market growth by providing resources, raising awareness, and improving access to PTSD treatments.

Opportunity

• Advancements in personalized medicines

Advancements in genetics and biomarker research offer opportunities for personalized medicine approaches in PTSD management. Identifying genetic and molecular markers associated with PTSD susceptibility and treatment response can help tailor interventions to individual patients. This approach has the potential to improve treatment outcomes and minimize adverse effects by targeting specific biological pathways and optimizing therapy based on patients' unique characteristics.

Furthermore, the rising collaboration, merger, and acquisition among the market players will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the rising number of market players will further expand the market's growth rate in the future. 

Restraint/Challenge

• High Cost Associated with The Product Manufacturing

On the other hand, the high cost associated with product manufacturing is expected to obstruct market growth. Also, the disruption in the supply chain industry has the potential to challenge the market’s growth. Also, the lack of favorable reimbursement scenarios and technology penetration in the developing economies, and the lack of suitable infrastructure are projected to challenge the market in the forecast period of 2023-2030.

This global post-traumatic stress disorder (PTSD) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Global Post-Traumatic Stress Disorder (PTSD) Market, contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Recent Development

• In 2021, Tonix Pharmaceuticals received Fast Track designation from the U.S. FDA for its investigational drug TNX-102 SL for the treatment of PTSD
• In 2020, AstraZeneca entered into a collaboration with Vanderbilt University to develop and commercialize compounds targeting the corticotropin-releasing factor 1 (CRF1) receptor for the potential treatment of PTSD and other mental health disorders.

Global Post-Traumatic Stress Disorder (PTSD) Market Scope

The global (PTSD) market is segmented on the basis of product, application, and end users. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.

Product

• Antidepressants
• Cognitive Therapy
• Anti-Anxiety Drugs
• Exposure Therapy
• Eye Movement Desensitization and Reprocessing (EMDR)
• PSTD therapeutics

Application

• Children
• Adult

End Use

• Hospitals
• Clinics

Global Post-Traumatic Stress Disorder (PTSD) Market   Regional Analysis/Insights

Global post-traumatic stress disorder (PTSD) market is analyzed, and market size insights and trends are provided by product, application, and end use as referenced above.

The countries covered in the global Post-Traumatic Stress Disorder (PTSD) market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa.

North America is expected to dominate the market due to rising healthcare costs, increased R & D, and trending technological advancements.

Asia-Pacific is expected to witness the fastest growth during the forecast period of 2023 to 2030 because of the rising strategic initiatives by the key market players and favorable government initiatives in the region.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The PTSD market also provides you with a detailed market analysis for every country’s growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the market, the impact of technology using life line curves, and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2015-2021

Competitive Landscape and Post-Traumatic Stress Disorder (PTSD) Market Share Analysis

The market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to) market.

Some of the major players operating in the post-traumatic stress disorder (PTSD) market are:

• GlaxoSmithKline plc. (U.K.)
• Pfizer Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• H. Lundbeck A/S (Denmark)
• Azevan Pharmaceuticals, Inc. (U.S.)
• Marinus Pharmaceuticals, Inc. (U.S.)
• Tonix Pharmaceuticals Holding Corp. (U.S.)
• Bionomics (Australia)
• Greenstone LLC (U.S.)
• Mylan NV(U.S.)
• Otsuka Pharmaceutical Co., Ltd (Japan)
• Prometheon Pharma, LLC. (U.S.)
• Ligand Pharmaceuticals Incorporated (U.S.)
• ライセラ（米国）
• JSC Valenta Pharm.（ロシア）
• ヌーボ・ファーマシューティカルズ社（カナダ）
• 振翔電気機械技術（上海）有限公司（中国）
• アストラゼネカ（英国）
• ニューロクラインバイオサイエンス社（米国）

SKU-57481